Condition category
Cancer
Date applied
14/08/2017
Date assigned
24/08/2017
Last edited
13/06/2018
Prospective/Retrospective
Retrospectively registered
Overall trial status
Ongoing
Recruitment status
No longer recruiting

Contact information

Type

Scientific

Primary contact

Dr Nigar Syed

ORCID ID

Contact details

Oxford Imaging Trials Unit
Department of Radiology
Surgical And Diagnostic Building
Churchill Hospital
Old Road
Headington
Oxford
OX3 7LE
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

33659

Study information

Scientific title

Biological magnetic resonance imaging parameters in oropharyngeal squamous cell carcinoma (BIOPIC): a non-randomised study

Acronym

BIOPIC

Study hypothesis

This study will investigate new MRI scanning techniques in patients undergoing radiotherapy treatment for squamous cell oropharyngeal (head and neck) cancer. We are looking at whether there are any changes in the cancer when the patient breathes in additional oxygen or carbogen (oxygen with carbon dioxide). This is important as tumours with low oxygen tend to be less responsive to treatment with chemotherapy or radiotherapy. We are also looking at a new method of imaging glucose (sugar) as this is taken up by cancer cells more than normal cells. We currently use FDG-PET/CT scans to image glucose but this involves radiation, unlike MRI. Patients will be asked to have an extra MRI scan before, during and after treatment to look at changes seen with the new MRI techniques we are investigating. We will also be taking blood samples and accessing tissue samples, such as routine biopsies taken as part of clinical care. We will look at the changes that occur with treatment, both under the microscope and through genetic testing. We will then compare this information to the findings from the MRI scans and other scans done routinely as part of patient care. We are interested to see if the new MRI techniques might be useful to monitor cancer patients having treatment or to predict whether they are likely to respond to therapy. In future this may allow us to choose the right treatment for a patient or to modify a treatment to improve response. This study is funded by the Oxford Cancer Imaging Centre and the Oxfordshire Health Services Research Committee. Recruitment will take place at the Churchill Hospital, Oxford.

Ethics approval

Gwasanaeth Moeseg Ymchwil Research Ethics Service, 08/02/2017, ref: 17/WA/0033

Study design

Non-randomised; Both; Design type: Diagnosis, Process of Care, Imaging, Cohort study

Primary study design

Interventional

Secondary study design

Non randomised study

Trial setting

Hospitals

Trial type

Diagnostic

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Specialty: Cancer, Primary sub-specialty: Head and Neck Cancer; UKCRC code/ Disease: Cancer/ Malignant neoplasms of lip, oral cavity and pharynx

Intervention

This is an observational study to assess novel MRI imaging techniques T1 and T2* with supplemental oxygen and carbogen breathing and CEST. Baseline scans will be compared to imaging during and post treatment in patients undergoing radiotherapy for oropharyngeal squamous cell carcinoma. For glucoCEST, comparison to DCE-MRI and contemporaneous clinical FDG-PET will also be undertaken. An exploratory study will investigate immunohistochemical and genetic markers related to factors influencing response to radiotherapy and compare these to findings on imaging.

Patient will be recruited from a single centre (Oxford University Hospital Foundation Trust) and will receive standard treatment and follow-up as part of routine NHS care. 15 patients (group A) will undergo study MRI lasting no more than one hour at three time points (baseline, during and after radiotherapy). A subgroup of participants (group B) will have an additional MRI at baseline i.e. 4 study MRI scans in total. Every patient who agrees to participate in the study and is felt by the investigator to be suitable will be asked if they are willing to be part of group B until a total of 5 participants is reached. From seeking informed consent, patients will be followed until post-treatment imaging which takes place 10-12 weeks after completion of radiotherapy. The duration of patients participation will be approximately 4 months.

Intervention type

Other

Phase

Drug names

Primary outcome measure

Changes in tumour T1 and T2* imaging with supplemental oxygen at baseline, week 2 radiotherapy and 10 weeks post radiotherapy

Secondary outcome measures

1. CEST signal with and without supplemental oxygen, measured at baseline, week 2 RT and 10 weeks post RT
2. T1, T2* and CEST signal with supplemental carbogen, measured at baseline, week 2 RT and 10 weeks post RT
3. Changes in GlucoCEST pre & post glucose load and markers such as choline, creatine, lactate, APT, measured at baseline, week 2 RT and 10 weeks post RT
4. FDG-PET parameters including SUVmax, uptake volume, measured at baseline and 10 weeks post RT
5. Standard DCE-MRI parameters such as ktrans, Ve, AUC compared with dynamic glucoCEST signal changes such as AUC, measured at baseline, week 2 RT and 10 weeks post RT
6. Consistency of MRI parameter measurements, evaluated using test-retest imaging at baseline in a subgroup of participants

Overall trial start date

07/06/2016

Overall trial end date

06/09/2019

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Participant is willing and able to give informed consent for participation in the study
2. Male or female, aged 18 years or above
3. HPV-positive oropharyngeal squamous cell carcinoma for treatment with radical radiotherapy +/- systemic therapy
4. The tumour is at least T2 or if nodal disease is used as the treatment assessment site, the node is at least 2 cm in minimum diameter on MRI
5. In the Investigator’s opinion, is able and willing to comply with all study requirements
6. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study
7. Involvement in other clinical studies is acceptable

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

Planned Sample Size: 20; UK Sample Size: 20

Participant exclusion criteria

1. Female participant who is pregnant, lactating or planning pregnancy during the course of the study
2. Significant renal or hepatic impairment
3. Type 1 diabetes mellitus or poorly controlled T2 diabetes mellitus or fasting capillary/venous blood glucose level > 8mmol/L.
4. Ongoing supplemental oxygen as part of clinical care
5. Known lung disease with carbon dioxide retention, chronic obstructive airways disease with known or at risk of hypercapnia
6. Most recent available arterial blood gas (ABG) from the current hospital admission demonstrates hypoxia or hypercapnia on room air
7. Any patient not felt to be suitable for supplemental oxygen or carbogen as considered by an appropriately trained clinician
8. Contraindication to MRI (e.g. cardiac pacemaker, ferromagnetic cerebral aneurysm clip, metallic foreign body in the eye)
9. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study

Recruitment start date

24/04/2017

Recruitment end date

06/09/2018

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Oxford Imaging Trials Unit
OX3 7LE
United Kingdom

Sponsor information

Organisation

University of Oxford

Sponsor details

Clinical Trials and Research Governance
University of Oxford
Joint Research Office
Block 60
Churchill Hospital
Oxford
OX3 7LE
United Kingdom

Sponsor type

University/education

Website

Funders

Funder type

Charity

Funder name

Cancer Research UK

Alternative name(s)

CRUK

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The intention is to publish this research in a specialist peer reviewed scientific journal on completion of the study. The results may also be presented at scientific meetings and/or used for a thesis. No study results may be published or presented without the prior approval of the TMG. Intend to publish before one year after overall trial end date.

IPD sharing statement:
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date

06/09/2020

Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

13/06/2018: Cancer Research UK lay summary link added to plain English summary field 14/05/2018: Internal review. 13/04/2018: Internal review 16/01/2018: Internal review. 25/10/2017: The ISRCTN prospective/retrospective flag compares the date of registration with the recruitment start date and does not include any grace period. The registration of this study was requested through the NIHR Portfolio and was finalised within 6 months of the recruitment starting. 16/10/2017: Internal review.